Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: Preliminary study

Cancer Biotherapy and Radiopharmaceuticals

Volumn 11, Issue 4, 1996, Pages 235-245

  Inoue, Tomio ^a   Kim, E Edmund ^a,b   Wallace, Sidney ^a   Yang, David J ^a   Wong, Franklin C L ^a   Bassa, Pedro ^a   Cherif, Abdallah ^a   Delpassand, Ebrahim ^a   Buzdar, Aman ^a   Podoloff, Donald A ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; FLUORINE 18; RADIOPHARMACEUTICAL AGENT; TAMOXIFEN DERIVATIVE; TRACER;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; BREAST CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THORAX RADIOGRAPHY;

EID: 9544244884     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1996.11.235     Document Type: Article

References (27)

1. Jordan VC. The role of tamoxifen in the treatment and prevention of breast cancer. Current Problems in Cancer 1992;16:129-176.
2. Wittliff JL. Steroid-hormone receptors in breast cancer Cancer 1984;53:630-643.
3. 18F]Fluoro-16a-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J Nucl Med 1991;32:1532-1537.
4. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors Radiology 1988;169:45-48.
5. McGuire AH, Dehdashti F, Shiegel BA, et al Positron tomographic assessment of 16a-[18F]fluoro-17β-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991;32:1526-1531
6. Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ. Preparation of four fluorine-18-labeled estrogens and their selective uptake in target tissue of immature rats. J Nucl Med 1984;25:1212-1221.
7. Brodack JW, Kilbourn MR, Welch MJ, Katzenellenbogen JA. Application of robotics to radiopharmaceutical preparation: controlled synthesis of fluorine-18-16a-fluoroestradiol-17ß. J Nucl Med 1986;27:714-721.
8. Kenady DE, Pavlik EJ, Nelson K, et al. Images of estrogen-receptor-positive breast tumors produced by estradiol labeled with iodine 1123 at 163. Arch Surg 1993;128:1373-1381.
9. 123I]iodoestradiol and its interaction with the estrogen receptor in vivo and in vitro. J Nucl Med 1989;30:209-215.
10. Jordan VC. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 1993;110:507-517.
11. Green S. Modulations of oestrogen receptor activity by oestrogens and antioestrogens. J SteroidBiochem Mol Biol 1990;37:747-751.
12. O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB. Inhibition of protein kinase C bytamoxifen. Cancer Res 1985;45:2462-2465.
13. Edashige K, Sato E, Akimaru K, Yoshida T, Utsumi K. Nonsteroidal antiestrogen suppresses protein kinase C:its inhibitory effect on interaction of substrate protein with membrane Cell Struct Funct 1991;16:273-281.
14. Lam H.Y. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun 1984;118:27-32.
15. Pollak MN, Huynh HT, Lefevre SP. Tamoxifen reduces serum insulin-like growth factor 1 (IGF-1). Breast Cancer Res Treat 1992;22:91-95.
16. Rose DP, Chlebowski RT, Connolly JM, Jones LA, Wynder EL Effects of tamoxifen adjuvant therapy and a low-fat diet or serum binding proteins and estradiol bioavailability in postmenopausal breast cancer patients. Cancer Res 1992;52:5386-5390.
17. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In: DeVita VT, Hellman JrS, Rosenberg SA. Cancer : Principles & Practice of Oncology. 4th ed Vol 1 Philadelphia: JB Lippincott Company; 1993:1264-1332
18. 18 [ F]fluorotamoxifen for imaging breast tumors. J Drug Targeting 1993;1:259-267
19. Yang DJ, Li C, Kuang L-R, et al. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Sciences 1994;55:53-67
20. Yang DJ, Tewson T, Tansey W, et al. Halogenated analogues of tamoxifen: synthesis, receptor assay and inhibition of MCF7 cells J Pharm Sci 1992;81:622-625.
21. Mullani NA, Gould KL, Hartz RK, et al. Design and performance of Posicam 6.5 BGO positron camera. J Nucl Med 1990;31:610-616.
22. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxyglucose: variations with body weight and a method for correction Radiology 1993;189:847-850.
23. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 1991;51:4837-4844.
24. Lien EA, Solheim E, Lea O, Lundgren S, Kvinnsland S, Ueland PM. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment Cancer Res 1989;49:2175-2183.
25. Wiseman H, Cannon M, Arnstein HRV, Halliwell B. Tamoxifen inhibits lipid peroxydation in cardiac microsomes: comparison with liver microsomes and potential relevance to the cardiovascular benefits associated with cancer prevention and treatment by tamoxifen. Biochem Pharmacol 1993;45:1851-1855
26. Roth RR, Vinegar A. Action by the lungs on circulating xenobiotic agents, with a case study of physiologically based pharmacokinetic modeling of benz(a)pyrene disposition. Pharmacol Ther 1990;48:143-155.
27. 18F]fluoro)-estradiol in DMBA-induced mammary tumors. Nucl Med Biol 1987;14:15-25.